
NAPOLI 3, POUT, & Ivosidenib - Azole DDIs
OncoPharm
00:00
Trial results and statistical versus clinical significance
John presents median OS (11.1 vs 9.2 months), HR 0.83, and contrasts statistical significance with modest clinical benefit.
Play episode from 06:26
Transcript


